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Abstract
The aim of the study was to review the epidemiology and prognosis of candidemia in a secondary hospital, and to examine
the intra-hospital distribution of candidemia patients. Study design is a retrospective cohort study. Trough 2002–2012, 110
cases of candidemia were diagnosed, giving an incidence of 2, 6/100000 citizens/year. Overall prognosis of candidemia was
dismal, with a 30 days case fatality rate of 49% and one year case fatality rate of 64%. Candidemia was a terminal event in
55% of 30 days non-survivors, defined as Candida blood cultures reported positive on the day of death or thereafter (39%),
or treatment refrained due to hopeless short-term prognosis (16%). In terminal event candidemias, advanced or incurable
cancer was present in 29%. Non-survivors at 30 days were 9 years (median) older than survivors. In 30 days survivors,
candidemia was not recognised before discharge in 13% of cases. No treatment were given and no deaths or complications
were observed in this group. Candidemia patients were grouped into 8 patient categories: Abdominal surgery (35%),
urology (13%), other surgery (11%), pneumonia (13%), haematological malignancy (7%), intravenous drug abuse (4%), other
medical (15%), and new-borns (3%). Candidemia was diagnosed while admitted in the ICU in 46% of patients. Urology
related cases were all diagnosed in the general ward. Multiple surgical procedures were done in 60% of abdominal surgery
patients. Antibiotics were administered prior to candidemia in 87% of patients, with median duration 17 (1–108) days.
Neutropenia was less common than expected in patients with candidemia (8/105) and closely associated to haematological
malignancy (6/8). Compared with previous national figures the epidemiology of invasive candidiasis seems not to have
changed over the last decade.
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Introduction
The epidemiology of invasive candidasis varies between regions
and countries, with higher rates in north-America than in Europe,
and an increasing north-south gradient observed in both [1].
Within Scandinavia an unexplained difference exists with high
incidence in Denmark and low incidence in the other Nordic
countries [2–5]. Mortality associated with candidemias has been
reported in the 40–70% range across a number of studies [6–8].
However, unbiased attributable candidemia mortality is difficult to
establish, and the effect of treatment in reducing overall mortality,
especially in low prevalence settings remains unclear. Risk factors
such as central line catheters, parenteral nutrition, steroids,
antibiotic usage, renal replacement therapy and diabetes are well
recognised but present too often to discriminate patients at risk,
and proposed prediction rules are of limited value in low-incidence
settings [9–12]. Patients undergoing multiple abdominal surgery,
suffering from haematological malignancies, or residing in ICU’s
are recognized risk groups [10,13], but otherwise data on the
intra-hospital epidemiology of candidemia is scarce. The aims of
study were threefold 1) To investigate the epidemiology of
candidemia from 2002–2012 compared with Norwegian national
figures for the previous 13 year period [14] 2) To investigate
overall outcome and elucidate attributable mortality looking into
differences between 30 days survivors and non-survivors, as well as
quantifying the risk factors antibiotic usage and surgeries prior to
candidemia and 3) To investigate differences in the in-hospital
epidemiology of candidemia across wards and specialities,
hypothesising candidemia patients would be found predominantly
in a limited number of clinical recognisable groups. Exploring this,
we attempted grouping candidemia patients into defined and
recognisable categories, and investigated differences in candidemia
incidence in medical and selected surgical departments. The study
was performed in a large secondary referral hospital with a
catchment area covering 7–10% of the Norwegian population,
encompassing a broad range of medical and surgical specialities.
Materials and Methods
Design
Retrospective cohort study including all patients $18 years of
age admitted from 01.01.2002 until 31.12.2012. Four patient’s #
18 years of age and 1 patient with missing data (5/110) were
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included in the calculation of population-based incidence, but not
in the other analyses.
Setting
Akershus University Hospital is a 650 bed secondary referral
hospital, with a catchment area comprising 320000 inhabitants up
to 2010 thereafter 460 000 inhabitants or almost 10% of the
Norwegian population. All specialities except neurosurgery, heart
surgery and transplant surgery are covered. The haematology
department is among the largest in Norway, but leukaemia
induction and bone marrow transplant therapies are not
performed. From 2005–2012, 2193 patients (0, 68% of total)
were discharged from the hospital with primary or co-diagnosis
neutropenia (ICD-D70). The ICU is a combined medical and
surgical ICU with 10 beds, where the majority of patients are in
need of ventilator support (2200 ventilator days 2012).
Microbiological sampling
During the study period 251799 blood culture bottles were
incubated, with median annual positive rate of 6, 8% (range 5, 4–
7, 2) over the study period. Candida albicans was in 2011 and
2012 ranked the 12 and 15 most common findings in blood
cultures with 18 and 10 unique patients as compared with 235 and
265 for the number one E.coli. Hospital blood sampling routines
requires two 10 ml bottles of blood drawn from 2 separate sites
(total 40 ml). The BACTEC9240 system was used until 2008,
thereafter the BACTEC FX20. All positive cultures were sent to
the national reference laboratory for confirmation and further
identification and susceptibility testing. An episode was considered
unique if single, or if not, occurring $21 days apart or caused by
different species. Catheter related candidemia was defined
according to IDSA guidelines [15].
Patient identification and data extraction
Candidemia cases were identified in the database of the
department of microbiology. Relevant study data were extracted
from the electronic patient charts. The following data were recorded:
age, gender, Candida species, admission ward, ICU stay during
shortly before or after (,5 days) a positive Candida blood culture,
diagnosis, Simplified Acute Physiology Score II (SAPS II) score (ICU
patients), number and type of surgical procedures, antibiotic days
prior to positive Candida blood culture, central venous lines, positive
central venous line catheter cultures, parenteral nutrition, neutro-
penia, diabetes, immunosuppression defined as metastatic cancer,
immunosuppressive medication other than steroids (recorded
separately), and in hospital and end of study mortality. Two
investigators categorised patients into 6 major diagnostic categories,
3 surgical and 3 medical according to organ responsible for
hospitalisation or speciality involved in management, or with other
clear defining characteristics such as preterm or intravenous drug
abuse. In ambiguous cases criteria were re-examined and a
consensus reached. In both surgical and medical patients a category
‘‘other’’ had to be created for groups with multiple diagnoses and
diverse major surgery, constituting 28/105 (27%) of the cohort.
Statistical analysis
Incidence of unique episodes was calculated correcting changes
in population, especially the increase in catchment area at the end
of study period. Incidence confidence intervals were calculated
according to the Byar approximation [16]. Standard descriptive
statistics were performed using mean (SD) or median (range) as
appropriate. The associations between time to death from last
positive blood culture and diagnostic categories were investigated
by Kaplan-Meyer survival plots and log rank tests. P-values are
two-tailed. Statistical analyses were performed using StatView
5.0 SAS Institute Inc.
Ethical considerations
The study protocol was presented to the Regional Ethical
Committee of South-Eastern Norway (REK) and approved as not
requiring patient informed consent. The Internal Privacy
Ombudsman of Akershus University Hospital approved the study,
and patient information was anonymized and de-identified prior
to analysis.
Results
110 individual patients with candidemia were identified over the
11 years period, several with multiple positive cultures, giving an
incidence of 2, 6/100000 citizens/year of unique episodes.
Candida albicans was by far most prevalent, species distribution
and susceptibility patterns are shown in table 1. Candidemia
incidence proportions per 1000 discharged patients from general
Medical, Haematological, Gastro-surgical, and Urology- wards are
shown in table 2. Patients received anti-fungal therapy according
to susceptibility results, except in 28 cases were blood cultures
became positive on the day of death or thereafter (n = 20), or the
candidemia was considered a terminal event and treatment
refrained (n = 8). Another 7 patients were discharged untreated
before candidemia was recognized, all cases without clinical
consequences (Table 3). Fluconazol was the most used empirical
antifungal, with an increased use of ecchinocandins empirically
towards the end of the period, rapidly de-escalating to fluconazole
in stable patients. Except in a few selected haematological patients,
antifungals were not used for prophylaxis. Thirty days case fatality
rate was 49%, and one-year mortality was 64%. Analysing survival
according to clinical categories revealed three distinct patterns,
with the clinical categories Intravenous Drug Use (IDU) (30 days
case fatality 0) and Urology (30 days case fatality 0,29) having
significant lesser case fatality than all other categories (30 days case
fatality 0,50–0,62). A Kaplan Meier plot is depicted in figure 1.
Follow-up for 90 and 1 year did not change this pattern (data not
shown). Advanced or incurable cancer was present in 15 patients
in the 30 days non survivors group, and in 5 surviving 30 days,
median survival in this latter group was 82 days, and only one
survived more than a year (range 38–485 days). Median age in
non-survivors at 30 days was 74 years (range 31–93) versus 65
years (range 24–92) in survivors. Distribution of antibiotic days
prior to candidemia and other established risk factors are shown in
table 4. Mean SAPS II score in the ICU candedima patients was
49 (SD 15). Catheter related candidemia was diagnosed in13
patients (12%), evenly distributed between the clinical recognisable
category Pneumonia and Haematological. Within the Gastro-
surgery category perforated viscus or anastomosis leakage were
present in18/37 (49%) and pancreatitis in 5/37 (13%) patients.
22/37 (59%) of patients underwent at least 2 abdominal surgical
procedures before or shortly after occurrence of candidemia. In
10/37 (27%) patients between 3 and 8 surgical procedures were
performed. Among the patients categorised in the Urology
category 11/14 (79%) had obstructive uropathy with a foreign
body, 9/14 (64%) either replaced or got a new nephrostomy in
close temporal relation to the candidemia.
Discussion
The candidemia incidence of 2,6/100 000/year remain low
compared with the Norwegian national incidence rate of 2,4/
Nosocomial Candedimia, Risk Factors and Prognosis
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100 000/year for the preceding 13 years (1991–2003) [14].
Numbers are not completely comparable, as bone marrow and
solid organ transplants are not accounted for by the present study,
and these high risk patients could contribute to higher overall
incidence on a national level. No major shift in the distribution of
isolates was seen, in particular the dominance, even increase of the
proportion of C.albicans (77%), was confirmed. Resistance
patterns continue to be favourable with all C.albicans susceptible
to fluconazole (table 1).
Absolute number of candidemias was highest in the medical
department, but the incidence were higher in the departments of
Gastro-surgery and Urology (table 2). Department of Cardiotho-
racic surgery counted 4/105 patients, all other specialities
accounted for only 1 or 2 (Neurology) patients each. Patients
admitted to medical wards present with more unclear and diverse
conditions. We therefore attempted to group all candidemia
patients independently from ward of admittance into clinical
recognisable categories according to organ responsible for
hospitalization, or specialty involved in management. Such
grouping was readily achieved in 75% of patients (table 4). More
than half (58%) could be categorized into established specialities;
Gastroenterological surgery, Urology, Haematology and Neonatal
medicine. Medical patients were more difficult to classify. Well
recognised risk groups such as intravenous drug abusers and
haematological malignancies comprised 10% of total, another
13% were categorised within a Pneumonia category. Of these,
64% were diagnosed in the ICU representing a subset of
pneumonia’s complicating other conditions such as cardiac arrest,
non-resolving sepsis, and organ failure.
Figure 1. Thirty days cummulative survival according to clinical recognisable categories. IDU and Urology compated to all other
categories (Other surgery, Abdominal surgery, Other medical, Pneumonia, Hematology). * Log rank test p = 0,0425.
doi:10.1371/journal.pone.0103916.g001
Table 1. Species distribution and in vitro antifungal susceptibility in 112 Candida blood culture isolates 2002–2012.
Candida species Number Fluconazole S/I/R Vorikonazole S/I/R AmphotericinB S/I/R Anidulafungin S/I/R Micafungin S/I/R
C. albicans 85 85/0/0 81/0/0 85/0/0 40/0/1 27/0/3
C. tropicalis 10 0/10/0 7/0/1 9/0/1 2/0/0 -
C. parapsilosis 10 7/2/1 9/0/1 9/0/1 0/5/0 0/5/0
C. glabrata 7 0/6/1 - 7/0/0 4/0/0 4/0/0
S/I/R categorisation according to EUCAST clinical breakpoints (v 6.1, available 2013-03-11) www.eucast.org.Some patients yielded more than one isolate, see text. All
isolates are not tested for all antifungals.
doi:10.1371/journal.pone.0103916.t001
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The relative importance of urology patients representing 14/
105 (13%) of candidemias in the cohort and with an incidence
proportion of 0, 46 (0, 24–0, 88) per 1000 patients admitted to the
urology department, was unexpected. Although urogenital candi-
diasis is recognised, the risk of candiduric patients developing
candidemia has been considered very low [17,18]. A distinctive
feature in urology patients was obstructive uropathy with a
nephrostomy or JJ stent in 11/14 patients. Urology patients were,
apart from the group intravenous drug abusers, also the only
group were no candidemias were diagnosed in the ICU. The
cumulative survival in the IDU and urology categories were also
higher compared to the other categories (Fig. 1). 20 of 37 patients
(54%) of the abdominal surgery category were diagnosed in the
ICU, leaving almost half of the group diagnosed on the regular
ward, as opposed to 9/12 (75%) diagnosed in the ICU in the
group other surgery. This left only 3 non-abdominal, non-urology
surgery patients diagnosed with candidemia in general surgical
wards over the whole 11 year period, stressing the role of major
and complicated surgery needing ICU surveillance for the
development of candidemia. Not only abdominal surgery per se,
but also ensuing complications were important for developing
candidemia, as 60% of abdominal surgery patients had at least two
surgical procedures performed, and 26% between 3 and 8. The
role of complications in this group was also reflected in days on
antibiotics prior to candidemia. With a median of 22 antibiotic
days it was the highest of all groups. These lengthy courses most
likely reflect a lack of control of underlying disease, as prolonged
antibiotic therapy is usually not required for abdominal surgical
infections. Long antibiotic courses prior to candedima were also
observed in medical patients, though with a median of 11–17 days,
shorter than abdominal surgery patients but comparable to all
other groups.
The lack of patients with profound and long lasting neutropenia
after allogenic bone-marrow transplant and acute leukaemia
induction therapies may explain that trough 2005–2012 only 8
out of 2193 patients discharged with neutropenia as a main or co-
diagnosis were diagnosed with candidemia. Six of these suffered
from hematologic malignancies. The findings emphasize the far
lower risk of candiemia following chemotherapy for solid tumours
or less aggressive lymphoma chemotherapy, representing the great
majority of neutropenic patients in this cohort.
With only 10 ICU beds out of a total of 650 hospital beds, ICU
patients accounted for 46% of all diagnosed candidemia’s. Mean
SAPS II score in the group was 49, which is higher than the mean
SAPS II of 40 that has been the average in our ICU over many
years. The increase in predicted mortality in this SAPS score
interval is steep, thus even within ICU patients candidemia
patients represent a subgroup with higher morbidity and worse
prognosis. The numbers of ICU patients in this study was higher
than in a Finnish and Scottish study [3,13,19] but in line with
studies from other investigators, reporting 33%–55% of candide-
mia episodes found in the ICU [20,21]. These differences may
reflect variations in specialities represented in the different settings,
especially solid organ and bone marrow transplantation activity.
As reported in other studies [22], we found high candidemia
case fatality rates with, 30 days mortality of 49% and 1 year
mortality of 64%. However, some observations raise questions
concerning candidemia attributable mortality and causality. In
particular, the observation that in 54% (28/52) of 30 days non-
survivors candidemia was a terminal event, with cultures
becoming positive on the day of death or thereafter, or the
patient considered in the process of dying and all active treatment
withdrawn. These findings would bias attributable mortality
significantly. This also applies to the observation of advanced or
incurable cancer in 54% (15/28) of terminal event candidemia
patients as opposed to 9% (5/53) in 30 days survivors. Further, the
median survival of advanced cancer patients in this latter group
was only 82 days, emphasizing the truly dismal short-term
prognosis of the combination of advanced cancer and candidemia.
Arguably the argument could be made that earlier and more
aggressive anti-fungal therapy could have prevented early deaths
and prolonged survival. From our detailed reading of the medical
records and involvement in treatment, we consider this a more
unlikely explanation. Interestingly, 7 patients in the 30 days
survivor group did not receive treatment due to unrecognized
positive blood cultures. Three of these had major but successfully
treated gastro surgical conditions (necrotizing cholecystitis, necro-
tizing pancreatitis, rectum perforation), two had minor urological
conditions, (bladder stone, catheter occlusion), one drug abuser left
hospital refraining treatment, and one patient was successfully
operated with hemicraniectomy following cerebral infarction.
Table 2. Candidemia incidence proportion (95% CI) per 1000 admitted per year, for patients above 18 years, in selected
departments* 2002–2012.
Department of
gastrosurgery Department of urology
Medical incl.
Hematological
department All departments
Incidence proportion (95% CI) 0,67 (0,47–0,94) 0,46 (0,24–0,88) 0,27 (0,20–0,34) 0,23 (0,19–0,28)
*data for department of admittance are not available for all department throughout the entire observational period.
95% CI calculated according to [15].
doi:10.1371/journal.pone.0103916.t002
Table 3. Clinical characteristics according to 30 days
outcome of candidemia.
Survivors Non-survivors
Number 54 51
Age (years)* 65 (24–92) 74 (31–93)
Terminal event: NA 28 (55)
- Culture positive on day of death or later NA 20 (39)
- Treatment refrained NA 8 (16)
- Advanced incurable cancer NA 15 (29)
- ICUadmittance NA 14 (27)
Advanced incurable cancer (all) 5 (9) 16 (31)
Not recognised before discharge 7 (13) NA
ICUadmittance 22 (41) 24 (47)
Values represent n (%) except * given as median (range).
doi:10.1371/journal.pone.0103916.t003
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Follow up medical history did not reveal any medical conse-
quences of neglected treatment. A possible explanation for the
benign outcome could be a transient nature of these candidemia’s
as opposed to a situation with continuous seeding form major extra
vascular foci, or continuous seeding from intravascular devices.
These cases do however underline the importance of resolving
underlying medical problems for the outcome of candidemia.
Thus in 35/105 (33%) of the whole cohort, lack of candidemia
treatment seems not to have had an influence on mortality or
morbidity.
Conclusions
In summary, the epidemiology of candidemia in this 11 years
survey in a secondary hospital setting seems largely unchanged
compared to the national incidence in the previous 13 years
period. No shift towards more non-albicans candidemias was
observed. In a general secondary referral hospital, urology
patients, and in particular patients with obstructive uropathy
may be an under-recognised risk group, and the risk for
neutropenic non-haematology patients may be overestimated.
ICU patients and patients with major complicated abdominal
surgery constitute the majority of patients. Candidemia seems to
be a terminal event in a significant proportion of patients, and one
year mortality suggests that an episode of candidemia is an
ominous sign. However, without major underlying disease,
candidemia may be a more benign condition than suggested by
the crude candidemia associated mortality.
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